BiotechTube
Home/Pipeline/Shared Antigen mRNA Cancer Vaccines

Shared Antigen mRNA Cancer Vaccines

Cancer

Phase 2Active

Key Facts

Indication
Cancer
Phase
Phase 2
Status
Active
Company
BioNTech

About BioNTech

BioNTech SE is a publicly-traded immunotherapy powerhouse founded by scientists and physicians to translate science into survival through innovative mRNA technologies. The company gained global recognition for its COVID-19 vaccine developed with Pfizer and is now applying its mRNA expertise to cancer immunotherapies and other infectious diseases. With over 25 Phase 2 and Phase 3 oncology trials and a €2.10 billion R&D investment planned for 2025, BioNTech is positioning itself as a leader in personalized cancer treatment and next-generation vaccines.

View full company profile

Therapeutic Areas

OncologyInfectious DiseasesImmunotherapy

Other Cancer Drugs

DrugCompanyPhase
Targeted Oncology TherapiesBioNTechPhase 1/2
ARGX-119ArgenxPhase 1
Oncology ProgramShionogiClinical
Bmab (Bevacizumab)BioconApproved
Ciforadenant (CPI-444)Corvus PharmaceuticalsPhase 1/2
Mupadolimab (CPI-006)Corvus PharmaceuticalsPhase 1
tovecimigCompass TherapeuticsClinical
CTX-8371Compass TherapeuticsClinical
XmAb 14045XencorClinical
XmAb 13676XencorClinical
VibostolimabXencorClinical
PB272 (neratinib, intravenous)Puma BiotechnologyNot Disclosed